The ABCA2 Knockout A-549 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma epithelial cell line, with targeted disruption of the ABCA2 gene encoding the ATP-binding cassette transporter A2. This polyclonal model enables loss-of-function studies of ABCA2 in a genetically heterogeneous background, suitable for investigating intracellular cholesterol trafficking and lipid homeostasis regulation without the clonal selection artifacts that may arise in monoclonal lines.
The A-549 cell line, established from a 58-year-old male patient, is an adherent epithelial cell line widely used as a model for lung adenocarcinoma. As cancerous alveolar basal epithelial cells, A-549 cells retain key signaling properties relevant to tumor biology, including drug resistance mechanisms and metabolic adaptations. This host line provides a physiologically relevant context for dissecting ABC transporter functions in lipid metabolism and oncogenic signaling, offering a robust platform for studying cholesterol-dependent processes in a malignant epithelial background.
ABCA2 encodes an ATP-binding cassette transporter that mediates intracellular cholesterol trafficking and lysosomal lipid handling, with critical roles in lipid raft organization and sterol homeostasis. ABCA2 expression is regulated by liver X receptor (LXR) agonists, oxysterols including 27-hydroxycholesterol, and the sterol regulatory element-binding protein 2 (SREBP2) transcription factor. Downstream, ABCA2 modulates amyloid precursor protein (APP) processing, lipid droplet formation, and myelin lipid metabolism, and functionally interacts with apolipoprotein E (APOE), low-density lipoprotein receptor (LDLR), ABCA1, and LDL receptor-related protein 1 (LRP1). Representative pathway components impacted by ABCA2 disruption include LXR, ABCA1, ABCG1, APOE, cytochrome P450 family 46 subfamily A member 1 (CYP46A1), and Niemann-Pick type C1 (NPC1).
In the A-549 adenocarcinoma background, ABCA2 is implicated in modulating drug sensitivity through altered cholesterol trafficking and membrane composition. Disruption of ABCA2 may compromise lipid raft integrity, potentially attenuating signaling cascades that promote tumor survival and chemoresistance. This polyclonal knockout model permits investigation of ABCA2-dependent mechanisms in lung cancer, including its contribution to cholesterol efflux pathways and cross-talk with the tumor microenvironment, thereby linking lipid dysregulation to malignant phenotypes.
Researchers can leverage this ABCA2 knockout polyclonal cell population for in vitro assays including RT-qPCR and western blotting to confirm target disruption, cholesterol efflux assays to quantify transporter activity, immunofluorescence and flow cytometry to detect altered protein localization, and drug uptake or MTT viability assays to assess chemosensitivity. Key applications encompass dissecting ABCA2-mediated drug resistance in lung adenocarcinoma, evaluating lipid metabolism in tumor progression, and analyzing functional interactions among ABC transporters. For further technical details and ordering information, please contact Ascent Research.
